Assessing Teleflex (TFX) Valuation After New Interventional Urology Clinical Results

Simply Wall St.05-27

Teleflex (TFX) has drawn fresh attention after releasing new clinical results for its Interventional Urology products, the UroLift System and Barrigel rectal spacer, at the AUA and ESTRO 2026 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638038145?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-05-27 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638038145","market":"us","top_or_hot":-1,"title":"Assessing Teleflex (TFX) Valuation After New Interventional Urology Clinical Results","media":"Simply Wall St.","content":"<div>\n<p>Teleflex (TFX) has drawn fresh attention after releasing new clinical results for its Interventional Urology products, the UroLift System and Barrigel rectal spacer, at the AUA and ESTRO 2026 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/assessing-teleflex-tfx-valuation-after-new-interventional-ur\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Teleflex (TFX) Valuation After New Interventional Urology Clinical Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Teleflex (TFX) Valuation After New Interventional Urology Clinical Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 15:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/assessing-teleflex-tfx-valuation-after-new-interventional-ur><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teleflex (TFX) has drawn fresh attention after releasing new clinical results for its Interventional Urology products, the UroLift System and Barrigel rectal spacer, at the AUA and ESTRO 2026 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/assessing-teleflex-tfx-valuation-after-new-interventional-ur\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/assessing-teleflex-tfx-valuation-after-new-interventional-ur","article_id":"2638038145","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/assessing-teleflex-tfx-valuation-after-new-interventional-ur","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638038145","pubTimestamp":1779865661,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Teleflex (TFX) has drawn fresh attention after releasing new clinical results for its Interventional Urology products, the UroLift System and Barrigel rectal spacer, at the AUA and ESTRO 2026 congresses, highlighting patient-centered outcomes.\nSee our latest analysis for Teleflex.\nTeleflex’s recent Interventional Urology data and dividend affirmation come as the stock trades at US$131.89, with the share price up 17.87% over 90 days but long term total shareholder returns still well below five...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","BK4504":"桥水持仓","TFX":"泰利福","BK4588":"碎股"},"translate_title":"评估Teleflex(TFX)在新的介入泌尿外科临床结果后的价值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TFX":1.5},"content_text":"Teleflex (TFX) has drawn fresh attention after releasing new clinical results for its Interventional Urology products, the UroLift System and Barrigel rectal spacer, at the AUA and ESTRO 2026 congresses, highlighting patient-centered outcomes. See our latest analysis for Teleflex. Teleflex’s recent Interventional Urology data and dividend affirmation come as the stock trades at US$131.89, with the share price up 17.87% over 90 days but long term total shareholder returns still well below five year levels. This suggests recent momentum is rebuilding from a weaker multi year base. If this kind of clinical and dividend story has your attention, it can be a good moment to broaden your research and uncover 34 healthcare AI stocks With Teleflex trading at US$131.89, sitting on an 8.9% gap to analyst targets and an indicated 41.1% intrinsic discount, investors now face a key question: is this genuine undervaluation, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 2% Overvalued Teleflex’s most followed narrative pegs fair value at $129.25 using an 8.9% discount rate, slightly below the last close at $131.89. This sets up a tight valuation debate.  The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.  Read the complete narrative. Want to see the full playbook behind that fair value line? The narrative leans on faster earnings expansion, richer margins, and a future earnings multiple that tells a very different story from today. Result: Fair Value of $129.25 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on UroLift weakness and ongoing margin pressures not deepening, and on the BIOTRONIK integration avoiding cost overruns or disruption to earnings. Find out about the key risks to this Teleflex narrative. Another Angle on Teleflex’s Valuation The narrative model has Teleflex 2% overvalued around a fair value of $129.25, yet Simply Wall St’s DCF model points to a future cash flow value of $223.78, or a 41.1% gap to the current $131.89 price. Two frameworks, one stock: which one feels closer to how you think about risk? Look into how the SWS DCF model arrives at its fair value. TFX Discounted Cash Flow as at May 2026Next Steps Curious whether the balance of risks and rewards here matches your own read of Teleflex? Take a close look at the underlying data, weigh both angles carefully, and then pressure test your view against our breakdown of 2 key rewards and 3 important warning signs Looking for more investment ideas? Before you move on, give yourself a chance to spot opportunities you might otherwise miss by running a few focused screens tailored to different goals.  Zero in on financially robust businesses by scanning the solid balance sheet and fundamentals stocks screener (46 results), which may better handle bumps in the road. Hunt for potential value by reviewing the 46 high quality undervalued stocks, which pair quality fundamentals with pricing that may not fully reflect them. Broaden your opportunity set by checking the screener containing 22 high quality undiscovered gems, which sit off the usual radars yet still show solid underlying metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teleflex might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638038145","isCrawlerRequest":true}